These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 14747537)

  • 1. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.
    Zhang H; Zhou Y; Alcock C; Kiefer T; Monie D; Siliciano J; Li Q; Pham P; Cofrancesco J; Persaud D; Siliciano RF
    J Virol; 2004 Feb; 78(4):1718-29. PubMed ID: 14747537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
    Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
    J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
    Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
    J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.
    Simon V; Padte N; Murray D; Vanderhoeven J; Wrin T; Parkin N; Di Mascio M; Markowitz M
    J Virol; 2003 Jul; 77(14):7736-45. PubMed ID: 12829813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults.
    Barbour JD; Wrin T; Grant RM; Martin JN; Segal MR; Petropoulos CJ; Deeks SG
    J Virol; 2002 Nov; 76(21):11104-12. PubMed ID: 12368352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
    Trivedi V; Von Lindern J; Montes-Walters M; Rojo DR; Shell EJ; Parkin N; O'Brien WA; Ferguson MR
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1291-300. PubMed ID: 18844463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.
    Pingen M; Wensing AM; Fransen K; De Bel A; de Jong D; Hoepelman AI; Magiorkinis E; Paraskevis D; Lunar MM; Poljak M; Nijhuis M; Boucher CA;
    Retrovirology; 2014 Nov; 11():105. PubMed ID: 25575025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.
    Bleiber G; Munoz M; Ciuffi A; Meylan P; Telenti A
    J Virol; 2001 Apr; 75(7):3291-300. PubMed ID: 11238855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inclusion of full length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping.
    Robinson LH; Gale CV; Kleim JP
    J Virol Methods; 2002 Jul; 104(2):147-60. PubMed ID: 12088824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy.
    Frenkel LM; Wang Y; Learn GH; McKernan JL; Ellis GM; Mohan KM; Holte SE; De Vange SM; Pawluk DM; Melvin AJ; Lewis PF; Heath LM; Beck IA; Mahalanabis M; Naugler WE; Tobin NH; Mullins JI
    J Virol; 2003 May; 77(10):5721-30. PubMed ID: 12719565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of HIV constructs containing protease-reverse transcriptase fusion proteins on viral replication.
    Cherry E; Morin N; Wainberg MA
    AIDS; 1998 Jun; 12(9):967-75. PubMed ID: 9662192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mother-to-Child HIV Transmission Bottleneck Selects for Consensus Virus with Lower Gag-Protease-Driven Replication Capacity.
    Naidoo VL; Mann JK; Noble C; Adland E; Carlson JM; Thomas J; Brumme CJ; Thobakgale-Tshabalala CF; Brumme ZL; Brockman MA; Goulder PJR; Ndung'u T
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28637761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins.
    Cherry E; Liang C; Rong L; Quan Y; Inouye P; Li X; Morin N; Kotler M; Wainberg MA
    J Mol Biol; 1998 Nov; 284(1):43-56. PubMed ID: 9811541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.
    Resch W; Ziermann R; Parkin N; Gamarnik A; Swanstrom R
    J Virol; 2002 Sep; 76(17):8659-66. PubMed ID: 12163585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.
    Huang W; Gamarnik A; Limoli K; Petropoulos CJ; Whitcomb JM
    J Virol; 2003 Jan; 77(2):1512-23. PubMed ID: 12502865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant.
    Zondagh J; Basson AE; Achilonu I; Morris L; Dirr HW; Sayed Y
    Antivir Ther; 2019; 24(5):333-342. PubMed ID: 30958309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.